These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 16895048)

  • 1. Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees.
    ; Dixon DO; Freedman RS; Herson J; Hughes M; Kim K; Silverman MH; Tangen CM
    Clin Trials; 2006; 3(3):314-9. PubMed ID: 16895048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Issues in regulatory guidelines for data monitoring committees.
    DeMets D; Califf R; Dixon D; Ellenberg S; Fleming T; Held P; Julian D; Kaplan R; Levine R; Neaton J; Packer M; Pocock S; Rockhold F; Seto B; Siegel J; Snapinn S; Stump D; Temple R; Whitley R
    Clin Trials; 2004; 1(2):162-9. PubMed ID: 16281888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the independence of data monitoring committee in adaptive design clinical trials.
    Chow SC; Corey R; Lin M
    J Biopharm Stat; 2012; 22(4):853-67. PubMed ID: 22651119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethical issues during the conduct of clinical trials.
    Silverman H
    Proc Am Thorac Soc; 2007 May; 4(2):180-4; discussion 184. PubMed ID: 17494728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring participant safety in phase I and II interventional trials: options and controversies.
    Hibberd PL; Weiner DL
    J Investig Med; 2004 Nov; 52(7):446-52. PubMed ID: 15651260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creation of an institutional semi-independent data monitoring committee.
    Tannock LR; Barton-Baxter M; Stoops WW
    Clin Trials; 2019 Oct; 16(5):523-530. PubMed ID: 31257918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating and implementing data and safety monitoring plans.
    Terrin ML
    J Investig Med; 2004 Nov; 52(7):459-63. PubMed ID: 15651262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Data monitoring committees. Third pillar in the methodical conduct of clinical trials].
    Fischer T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):793-6. PubMed ID: 18563280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoepidemiology 101: data monitoring committees in the post-marketing approval setting.
    Lilienfeld DE
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):381-5. PubMed ID: 15170767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety panel backs principle of gene-therapy trials.
    Check E
    Nature; 2002 Dec; 420(6916):595. PubMed ID: 12478252
    [No Abstract]   [Full Text] [Related]  

  • 15. Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases.
    Filippatos GS; de Graeff P; Bax JJ; Borg JJ; Cleland JG; Dargie HJ; Flather M; Ford I; Friede T; Greenberg B; Henon-Goburdhun C; Holcomb R; Horst B; Lekakis J; Mueller-Velten G; Papavassiliou AG; Prasad K; Rosano GM; Severin T; Sherman W; Stough WG; Swedberg K; Tavazzi L; Tousoulis D; Vardas P; Ruschitzka F; Anker SD
    Eur J Heart Fail; 2017 Apr; 19(4):449-456. PubMed ID: 28271595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward protecting the safety of participants in clinical trials.
    Califf RM; Morse MA; Wittes J; Goodman SN; Nelson DK; DeMets DL; Iafrate RP; Sugarman J
    Control Clin Trials; 2003 Jun; 24(3):256-71. PubMed ID: 12757992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
    DeMets DL; Fleming TR; Whitley RJ; Childress JF; Ellenberg SS; Foulkes M; Mayer KH; O'Fallon J; Pollard RB; Rahal JJ
    Control Clin Trials; 1995 Dec; 16(6):408-21. PubMed ID: 8720018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On independent data monitoring committees in oncology clinical trials.
    Wittes J; Schactman M
    Chin Clin Oncol; 2014 Sep; 3(3):40. PubMed ID: 25841466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A third trial oversight committee: Functions, benefits and issues.
    Lane JA; Gamble C; Cragg WJ; Tembo D; Sydes MR
    Clin Trials; 2020 Feb; 17(1):106-112. PubMed ID: 31665920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.